{"name":"AgeneBio","slug":"agenebio","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AGB101","genericName":"AGB101","slug":"agb101","indication":"Alzheimer's disease","status":"phase_2"}]}],"pipeline":[{"name":"AGB101","genericName":"AGB101","slug":"agb101","phase":"phase_2","mechanism":"AGB101 is a monoclonal antibody targeting amyloid-beta","indications":["Alzheimer's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNeFlXMXIyT2hqc0tnRzNVMl9zX0c0TGdaWlZZaXFyNGpqUW11aHBGNlpXZHloaHI5SFpIRnRFX1UwSzBrZDlTUEdLMVgwbmNqa2FrVTJRbDVabHgyLWJGQlRwU2txUkY2ZXpyV3gzUGZEQTQ3MXJZTC1uX0JLMV9XOE9oemNZc294UllLYXFvRDB2MFBaNTdsZDU0bkZKb1JkSUNaVXV3S2ZEdzJheW9LYWxGS2c2NzZGN3pNYVR0ZndnQ3lMYmdXbEFyQXpSQVhDTER3T2VVclFTYl82bGtibDJlamU?oc=5","date":"2026-01-30","type":"regulatory","source":"fortune.com","summary":"This startup has the lead in longevity, securing the first FDA-approved partial de-aging human trial - fortune.com","headline":"This startup has the lead in longevity, securing the first FDA-approved partial de-aging human trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxQM2d3dE9nTnNjYzl0SFktSGFES1lmOUpmMjFWU19YVkF5dFhCa0pOTFJWdGkycHA3UzNhcGtaVTNlcnRLODVsWHJFaWlpeVJFZTFuVGR0NTgxanZNS2IwVS1VaWZIWXhPSm41am9sNHhGRnBpUFowZW9oYXlsTlQ4RW5VUEI1V0lmQ08xd21FRW43cnFMTFRZTkpVd2Vmc3JpMzBiaEJId0FpMk5YYjlXeWZSeEMwYmlGdldtcTJ3cW1TdEFuZXNuUlJyVldNRVFmemNmWm1vOFBqNW1wRWFHMTFkQlZoV1B4X3p1WHVVeTZnZGFUM3JUVQ?oc=5","date":"2025-02-04","type":"pipeline","source":"BioSpace","summary":"Memory Disorders Market Expected to Exhibit a CAGR of 5.49% During 2025-2035, Impelled by Growing Awareness and Early Diagnosis. - BioSpace","headline":"Memory Disorders Market Expected to Exhibit a CAGR of 5.49% During 2025-2035, Impelled by Growing Awareness and Early Di","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxNcHp2TDAyeEkzN3ljaU9BQUZpWkhuZDE2ZVRkc2xsWmJvWmZXWE9PTlM3UnN4Vk8yRW1XekhRUG9ZeUlLNE90VFF5YzBkYnNWUWxiaU8xRmxxbnZqekM2c0FLS3NEWm01ZHBqNVd6MUxoS2doWXk2QXY5OUUzQU50VVpPWHBzX0l4UmVBdUVqUHBZOU5GeUQzS1hYZ0t3MWxkSFBxNW9RbEdBdzI4THo2aUp0RGtQTi1vOTJHV1FNTVZLangydUZvWHNURjNlSmJINm5TRkRCTmUweG5kMGVNcF9mREJQMWxrSE9leTBfVHFhQXdNeFhyUTVyUUZPeUM1ZG9RRUxSa0NSaFJsbDdYamQ0YVJmbGh0cnRZcVc3Zzcwck84ZTVLWA?oc=5","date":"2025-02-01","type":"pipeline","source":"The Malaysian Reserve","summary":"Alzheimer's Disease Therapeutics Market to Grow by USD 5.41 Billion (2024-2028), Novel Biomarker R&D Boosts Growth, with AI Driving Market Transformation - Technavio - The Malaysian Reserve","headline":"Alzheimer's Disease Therapeutics Market to Grow by USD 5.41 Billion (2024-2028), Novel Biomarker R&D Boosts Growth, with","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOVHphUklkcC1iaVFiTzBSdllFN29pa2RVa05oa3RQRWdIUjBOaS1aLXNNTHVKeW5zVGRpck1PeTVCY19SNk9RQzdSS0x4bHdEWHEzLUI4MDFjY3NyenFCRm01MUliYk56YnU3c1lvSTRDX0IzY0l3dXhQeFlQUTV0OG1STGcxSGh6b3NOdXVXWXlhX3NlTGZFVm5fdm8zQ2ZMelE?oc=5","date":"2018-06-28","type":"pipeline","source":"Fierce Biotech","summary":"Neos poaches AgeneBio chief as CEO Vipin Garg abruptly resigns - Fierce Biotech","headline":"Neos poaches AgeneBio chief as CEO Vipin Garg abruptly resigns","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}